Could a 2-Visit rabies vaccine schedule offer the same protection as 3?
NCT ID NCT06066294
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial tests whether a two-visit rabies vaccine schedule (with two small doses on day 0 and day 7) is as safe and effective as the standard three-visit schedule (with one dose on days 0, 7, and 28) in healthy adults. The goal is to see if both schedules produce a strong immune response and to compare side effects. Participants will receive the rabies vaccine and have blood samples taken to measure antibody levels over a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rabies vaccine (Rabivax-S)
- What this could lead to
- If successful, this could lead to a simpler, shorter rabies vaccination schedule, making pre-exposure protection easier and more accessible.
- What could go wrong
- The trial is relatively small and results may not apply to everyone. There is also a risk of side effects, such as local reactions or allergic responses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VACCINE REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kempegowda Institute Of Medical Sciences Hospital and Research Center
Bengaluru, Karnataka, 560002, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.